Literature DB >> 2242413

Implementation of group sequential logrank tests in a maximum duration trial.

K K Lan1, J M Lachin.   

Abstract

To control the Type I error probability in a group sequential procedure using the logrank test, it is important to know the information times (fractions) at the times of interim analyses conducted for purposes of data monitoring. For the logrank test, the information time at an interim analysis is the fraction of the total number of events to be accrued in the entire trial. In a maximum information trial design, the trial is concluded when a prespecified total number of events has been accrued. For such a design, therefore, the information time at each interim analysis is known. However, many trials are designed to accrue data over a fixed duration of follow-up on a specified number of patients. This is termed a maximum duration trial design. Under such a design, the total number of events to be accrued is unknown at the time of an interim analysis. For a maximum duration trial design, therefore, these information times need to be estimated. A common practice is to assume that a fixed fraction of information will be accrued between any two consecutive interim analyses, and then employ a Pocock or O'Brien-Fleming boundary. In this article, we describe an estimate of the information time based on the fraction of total patient exposure, which tends to be slightly negatively biased (i.e., conservative) if survival is exponentially distributed. We then present a numerical exploration of the robustness of this estimate when nonexponential survival applies. We also show that the Lan-DeMets (1983, Biometrika 70, 659-663) procedure for constructing group sequential boundaries with the desired level of Type I error control can be computed using the estimated information fraction, even though it may be biased. Finally, we discuss the implications of employing a biased estimate of study information for a group sequential procedure.

Entities:  

Mesh:

Year:  1990        PMID: 2242413

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

1.  The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1.

Authors: 
Journal:  Control Clin Trials       Date:  1999-12

2.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

3.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

4.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

5.  Survival trial design and monitoring using historical controls.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2016-06-15       Impact factor: 1.894

6.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

7.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Authors:  Eugene Braunwald; Michael J Domanski; Sarah E Fowler; Nancy L Geller; Bernard J Gersh; Judith Hsia; Marc A Pfeffer; Madeline M Rice; Yves D Rosenberg; Jean L Rouleau
Journal:  N Engl J Med       Date:  2004-11-07       Impact factor: 91.245

8.  Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).

Authors: 
Journal:  Pediatr Diabetes       Date:  2007-06       Impact factor: 4.866

9.  Flexibly Monitoring Group Sequential Survival Trials When Testing is Based Upon a Weighted Log-Rank Statistic.

Authors:  Sean S Brummel; Daniel L Gillen
Journal:  Seq Anal       Date:  2014-01-30       Impact factor: 0.927

10.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.